

LAUNCH

Sexual and Reproductive Health Research & Development: Beyond Spillovers

11 October 2023

POLICY CURES RESEARCH.




G-FINDER Thematic areas



Poverty-Related Neglected Diseases




Emerging Infectious Diseases



Sexual and Reproductive Health




Beyond spillovers



- Sexually transmitted infections (STIs)
- HPV and HPV-related cervical cancer
- Contraception
- Multipurpose prevention technologies (MPTs)
- Pre-eclampsia and eclampsia
- Post-partum haemorrhage (PPH)
- R&D for more than one issue

SRH R&D funding 2018-2021


SRH R&D funding grew by \$200m, but funding not is not equal...



Total funding for SRH R&D by disease or health area (2018 – 2021)

Most of growth came from increases in sexually transmitted infection R&D funding...

Sexually transmitted infection R&D funding by product type (2018 – 2021)




SEXUALLY TRANSMITTED INFECTIONS

\$146 MILLION
LMIC-APPLICABLE R&D FUNDING IN 2021

Total R&D spend 2021	Cumulative R&D spend 2018-2021	Total R&D spend 2018-2021				% change from 2020	Sector share	R&D stage share
		18	19	20	21			
\$146m	\$488m					-8.9%↓	<div><div>Public</div><div>Philanthropic</div><div>Private</div></div>	<div><div>Basic & early</div><div>Late</div><div>Unspecified</div></div>

...as well as increases in related issues such as HPV and HPV-related cervical cancer

HPV & HPV-related cervical cancer R&D funding by product type (2018 – 2021)





HUMAN PAPILLOMAVIRUS AND RELATED CERVICAL CANCER

\$142
MILLION
LMIC-APPLICABLE
R&D FUNDING
IN 2021

Total R&D spend 2021	Cumulative R&D spend 2018-2021	Total R&D spend 2018-2021				% change from 2020	Sector share	R&D stage share
		18	19	20	21			
\$142m	\$456m					+17% ↑	<div><div>Public</div><div>Philanthropic</div><div>Private</div></div>	<div><div>Basic & early</div><div>Late</div><div>Unspecified</div></div>

- Unspecified
- Devices
- Diagnostics
- Microbicides
- Biologics
- Vaccines
- Drugs
- Basic research

Contraceptive R&D funding has largely stagnated, and started to fall




Contraception R&D funding by duration (2018 – 2021)

Duration	US\$ (millions)				Cumulative total	
	2018	2019	2020	2021	2021 % of total	
Long-acting reversible (LARC)	62	62	58	53	235	45
Short-acting	26	39	42	23	130	20
On-demand	4.1	7.3	4.1	4.4	20	3.8
Permanent	3.9	-	3.2	1.1	8.2	1.0
Multiple or unspecified duration	18	35	34	36	122	30
Total	114	144	141	117	516	100


- No reported funding

MPT R&D funding has rebounded from a two year dip



MULTIPURPOSE PREVENTION TECHNOLOGIES

\$49.9 MILLION
LMIC-APPLICABLE R&D FUNDING IN 2021




MPT R&D funding by indication (2018 – 2021)

Indication	US\$ (millions)				Cumulative total	
	2018	2019	2020	2021	2021	2021 % of total
Contraception + STI	40	15	11	30	95	59
Contraception + HIV	7.9	14	13	12	47	24
Contraception + STI + HIV	5.5	4.6	6.3	6.5	23	13
STI + HIV	0.6	2.8	1.8	1.1	6.2	2.2
Unspecified	2.1	0.8	1.6	0.6	5.1	1.3
Total	56	37	33	50	176	100

**But funding for maternal health
issues is lagging behind**


Preeclampsia & eclampsia R&D funding is steadily falling

Preeclampsia R&D funding by product type (2018 – 2021)



PREECLAMPSIA & ECLAMPSIA


\$20.7 MILLION
LMIC-APPLICABLE
R&D FUNDING
IN 2021



- Unspecified
- Devices & combinations
- Diagnostics
- Biologics
- Drugs
- Basic research

..as is funding for postpartum haemorrhage R&D

Postpartum haemorrhage R&D funding by product type (2018 – 2021)




POSTPARTUM HAEMORRHAGE

\$0.9 MILLION
LMIC-APPLICABLE R&D FUNDING IN 2021

Total R&D spend 2021	Cumulative R&D spend 2018-2021	Total R&D spend 2018-2021	% change from 2020	Sector share	R&D stage share
\$0.9m	\$16.0m	<div><div></div><div></div><div></div><div></div></div>	-56% ↓	<div><div></div><div></div></div>	<div><div></div><div></div></div>

Although the pipeline looks reasonable but isn't the full story...




PPH pipeline products includes candidates investigated to treat PPH from 2000-2023. Pipeline products for all other maternal health conditions includes candidates investigated between 2000-2021.

Looking past the numbers


Increasing share of burden in HICs is a reasonably accurate predictor of how much money was spent on it

Total R&D funding and burden of SRH health issues in high income countries 2021




SRH R&D has benefited from COVID-driven increased investments for platform technologies

Non-issue specific R&D funding by product type 2018-2021




Some
SRH R&D
funding is
becoming
more
diverse


Female vs male end users



Hormonal vs non-hormonal




User-controlled vs non-user-controlled




Funding for SRH
R&D has
become more
diverse...and
there is optimism
that this will
continue & grow

SRH funding flows 2018-2021



R&D to SRH vs COVID-19, HIV/AIDS & dengue 2021 (US\$ millions)

Overall though,
R&D funding to
SRH pales in
comparison to
other global
health areas



Q&A

Looking to the future of the G-FINDER SRH report

What criteria do we need to answer this question specifically with an LMIC lens?

Within a global health context, what is being spent and done in biomedical innovation for women's health?



Women's Health R&D:
a feminist lens
on global health R&D

Global health R&D ecosystem

e.g., inclusion/representation in CTs, preclinical/discovery,
R&D leadership roles, R&D priority setting, pipeline

**Neglected
diseases**

e.g., HIV, malaria, schistosomiasis

**Emerging Infectious
diseases**

e.g., COVID, Zika


**Sexual & reproductive
health**

e.g., STIs, HPV, contraception, MPTs, pregnancy-related
conditions, gynaecological health issues,
menstrual and menopause health

**Chronic &
non-communicable diseases**


e.g., cancers, heart disease, Alzheimer's

“Women’s health” is often defined in the context of conditions exclusive to women




But what about things that affect women disproportionately & differently?

??



But really we only have a fraction of the data...so far





Women's Health R&D: a feminist lens on global health R&D

Global health R&D ecosystem

e.g., inclusion/representation in CTs, preclinical/discovery, R&D leadership roles, R&D priority setting, pipeline

Neglected diseases

e.g., HIV, malaria, schistosomiasis

Emerging Infectious diseases

e.g., COVID, Zika

Sexual & reproductive Health +

e.g., STIs, HPV, contraception, MPTs, pregnancy-related conditions, gynaecological health issues, menstrual and menopause health

Chronic & non-communicable diseases

e.g., cancers, heart disease, Alzheimer's

Thank you!

POLICY CURES RESEARCH